Michael Osterholm is the author of Deadliest Enemy: Our War Against Killer Germs.

“The real challenge is that there is already an established, and very mature, private-sector enterprise producing flu vaccine that has in place a system of annual delivery that guarantees a certain amount of money,” said Michael Osterholm, the founder of the Center for Infectious Disease Research and Policy at the University of Minnesota. “How are you going to change that? Who is going to pay for that, given that the cost of research and development may mean the vaccine will be substantially more expensive than what we already have? What company will embrace that?” [SmithsonianMag.com]

Leave a Reply

Your email address will not be published. Required fields are marked *